Q1 Earnings Forecast for CNTA Issued By Leerink Partnrs

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Centessa Pharmaceuticals in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04.

Other research analysts have also recently issued reports about the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Stock Down 4.9 %

CNTA stock opened at $15.81 on Wednesday. The business’s 50-day simple moving average is $16.51 and its 200 day simple moving average is $16.43. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.08 billion, a PE ratio of -10.33 and a beta of 1.54. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the transaction, the insider now owns 183,266 shares of the company’s stock, valued at approximately $3,122,852.64. The trade was a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 11,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $185,460.00. Following the sale, the chief technology officer now owns 121,503 shares in the company, valued at $2,048,540.58. The trade was a 8.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 260,168 shares of company stock worth $4,316,568 in the last quarter. 11.59% of the stock is owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its position in Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after buying an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock worth $85,744,000 after purchasing an additional 924,027 shares during the period. Janus Henderson Group PLC raised its holdings in Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC lifted its position in Centessa Pharmaceuticals by 24.3% during the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock valued at $58,603,000 after purchasing an additional 684,391 shares during the period. Finally, Point72 Asset Management L.P. boosted its stake in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.